Accelerate Diagnostics (AXDX) announced the signing of a collaboration and quality agreement with Bruker Corporation (BRKR), the provider of the market-leading MALDI Biotyper system for microbial identification. This agreement enables both companies to validate the use of Accelerate Diagnostics’ Arc system, an innovative, automated positive blood culture sample preparation platform, with Bruker’s MALDI Biotyper sirius instruments and Sepsityper software for subsequent registration in both the US and EMEA markets.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AXDX:
Questions or Comments about the article? Write to editor@tipranks.com